Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenoviral Infection Clear all
Completed No phase listed Observational

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

NCT00490464
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions
Nicardipine and Nipride
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Jul 23, 2026, 10:57 PM EDT
Withdrawn Phase 2 Interventional

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

NCT03532035
View directory record Official record
Conditions
Adenovirus
Interventions
Brincidofovir, Standard of Care
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 23, 2026, 10:57 PM EDT
Withdrawn Phase 1 Interventional

Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)

NCT02276820
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Viralym-A
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 23, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

NCT05664126
View directory record Official record
Conditions
Cytomegalovirus, Adenovirus
Interventions
VST infusion, CliniMACS
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

NCT01979406
View directory record Official record
Conditions
Anthrax Infection
Interventions
AVA, Ad4-PA-1, Ad4-PA-GPI-1
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Kansas City, Kansas • Silver Spring, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

NCT01011712
View directory record Official record
Conditions
EBV, HSV, VZV, HPV, CMV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

NCT01570283
View directory record Official record
Conditions
Viral Infection
Interventions
Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

NCT02108522
View directory record Official record
Conditions
Infection
Interventions
Multivirus Specific T cells
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Recruiting Phase 1 Interventional

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

NCT06926894
View directory record Official record
Conditions
Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Columbia University
Other
Eligibility
3 Months to 26 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

NCT03583606
View directory record Official record
Conditions
Ebola Disease, Immunisation
Interventions
ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 23, 2026, 10:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

NCT04722029
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Adenovirus Specific T lymphocytes
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

NCT00695877
View directory record Official record
Conditions
HIV Infections
Interventions
Ad5.ENVA.48 HIV-1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309
View directory record Official record
Conditions
Norovirus Infection
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

NCT00321061
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 10:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

NCT05271318
View directory record Official record
Conditions
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
TILT-123, pembrolizumab, pegylated liposomal doxorubicin
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

NCT01070797
View directory record Official record
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Not applicable Interventional

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

NCT00266734
View directory record Official record
Conditions
Acute Conjunctivitis, Adenoviral Conjunctivitis
Interventions
RPS Adeno Detector
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
1 Month and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Springfield, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Jul 23, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

NCT01143181
View directory record Official record
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jul 23, 2026, 10:57 PM EDT